Garvin Joins DCI as Director of Research Development-Clinical Research
Published
From the Duke Cancer Institute archives. Content may be out of date.
Shanta Laurie Garvin MHSA, MPA, CRA, joined Duke Cancer Institute as Director of Research Development-Clinical Research on June 1, 2021.
In this new role, Garvin will lead and manage activities to enhance processes, prepare for continued growth, assure staff development, expand communication with investigators, identify and assist in developing areas for growth in clinical research funding, ensure that the use of new tools and best practices are optimized, and contribute to advancing the recognition of the work of the DCI through targeted communications and outreach.
"Shanta is a persuasive communicator and team-oriented leader who focuses on the big picture not to exclude or minimize how systems work together to establish and measure goals to reach desired outcomes," said Karen Kharasch, senior director of Research Strategy and Operations at DCI.
Garvin has 20 years of experience in research administration — grants, contracts, research billing — in both academic and healthcare settings, including Savannah State University, Emory University, Children’s Healthcare of Atlanta, and Vanderbilt University Medical Center. She has a Bachelor of Science in Political Science, a Masters in Public Administration- Policy Management, and a Masters- Health Services Administration.
As a Certified Research Administrator, Garvin's expertise lies in her comprehensive knowledge of best practices in sponsored research administration; knowledge of and application of institutional policies and their impact on daily operations; and establishing and maintaining relationships with stakeholders.
"She is a leader who encourages and supports teamwork, high-level customer service, and individual professional growth and development. Her career has provided a wide array of opportunities with increased levels of duties, responsibilities, and authority," said Kharasch. "She brings to us a wealth of knowledge, skills, and abilities and an open mind to learn and enhance the operations of clinical research administration within DCI."
A team at the Duke Cancer Institute (DCI) is launching a first-of-its-kind study that could bring new hope to patients living with advanced colorectal cancer.Led by medical student Cheryl Chang and DCI medical oncologist Nicholas DeVito, MD, the project explores why some colorectal cancers that spread to the liver respond well to chemotherapy while others do not. The team recently presented this research at the American Association for Cancer Research (AACR) Immuno-Oncology (IO) Conference.This type of cancer can be especially challenging to treat. Patients often face fewer effective options, and outcomes can vary widely. By taking a closer look at what’s happening inside the tumor before and after treatment, the Duke team hopes to uncover clues that could one day guide more personalized and more effective care.When colorectal cancer spreads to the liver at the time of diagnosis, it often means a tougher road ahead. Doctors know that these patients typically do not respond to chemotherapy the same way others do, but the reasons behind that difference remain unclear.“If we can understand why some patients don’t respond well, we may be able to adjust treatment earlier, or develop new options altogether,” Chang said.To do this, the team is studying tissue samples taken from patients before treatment, when the cancer is first discovered, and after about six months of chemotherapy, when surgeons remove part of the liver or colon.Looking at these pairs of samples gives researchers a rare opportunity to see how cancer and the immune system around it changes during treatment.This is the first known study to compare liver metastasis samples before and after chemotherapy in this specific patient group. Despite decades of using chemotherapy to treat colorectal cancer, surprisingly little is known about how treatment affects the immune environment inside these tumors.“This is an area that’s been largely unexplored,” DeVito said. “We’re excited to contribute something new that has the potential to change how we approach treatment.”A big focus of the study is the tumor microenvironment, the community of immune cells, cancer cells, and other structures within and around each tumor. Using two advanced technologies, the team examines the tumor at both the protein and RNA levels.Working with John Hickey, PhD, assistant professor of biomedical engineering at the Pratt School of Engineering, the team employed the Codex assay in the study. By using special antibodies to highlight different cell types, the assay lets researchers map where various immune cells are and how close they are to the tumor.The team also partnered with Erika Crosby, PhD, assistant professor in the Duke Department of Surgery, to use the Xenium assay, which analyzes the RNA within cells. This helps confirm the protein‑level findings while revealing additional details that might not show up at the protein stage.Early results show meaningful differences between patients who respond to chemotherapy and those who don’t. Some immune cells appear in higher numbers in people who respond well, suggesting these may serve as early indicators of how effective chemotherapy might be.“Without this collaboration between surgery and biomedical engineering, locating and reviewing patient records and samples would have been far more time‑consuming,” DeVito said. “Everything came together at the right time: the technology, the expertise, and access to the right samples. That’s what makes a project like this possible.”A major boost for this work also came from CRUSH Colorectal Cancer, which supports early‑stage ideas that need initial funding before they can compete for larger grants.“CRUSH provided the seed funding that allowed us to get started,” DeVito said. “An added benefit is that any data generated becomes a shared resource for the entire GI oncology team at Duke.”Looking ahead, the team plans to expand their research into mouse models in collaboration with Jatin Roper, MD, that mimic how colorectal cancer spreads to the liver. This could help them test the biomarkers they discover and explore new treatment strategies in the lab.“Ultimately, everything we’re doing comes back to the patient,” Chang said. “We want to find better ways to treat this cancer, especially for patients who don’t have many options today.”The annual CRUSH Colorectal Cancer 5K will be held on March 14. Learn more about the event.
A team at the Duke Cancer Institute (DCI) is launching a first-of-its-kind study that could bring new hope to patients living with advanced colorectal cancer.Led by medical student Cheryl Chang and DCI medical oncologist Nicholas DeVito, MD, the project explores why some colorectal cancers that spread to the liver respond well to chemotherapy while others do not. The team recently presented this research at the American Association for Cancer Research (AACR) Immuno-Oncology (IO) Conference.This type of cancer can be especially challenging to treat. Patients often face fewer effective options, and outcomes can vary widely. By taking a closer look at what’s happening inside the tumor before and after treatment, the Duke team hopes to uncover clues that could one day guide more personalized and more effective care.When colorectal cancer spreads to the liver at the time of diagnosis, it often means a tougher road ahead. Doctors know that these patients typically do not respond to chemotherapy the same way others do, but the reasons behind that difference remain unclear.“If we can understand why some patients don’t respond well, we may be able to adjust treatment earlier, or develop new options altogether,” Chang said.To do this, the team is studying tissue samples taken from patients before treatment, when the cancer is first discovered, and after about six months of chemotherapy, when surgeons remove part of the liver or colon.Looking at these pairs of samples gives researchers a rare opportunity to see how cancer and the immune system around it changes during treatment.This is the first known study to compare liver metastasis samples before and after chemotherapy in this specific patient group. Despite decades of using chemotherapy to treat colorectal cancer, surprisingly little is known about how treatment affects the immune environment inside these tumors.“This is an area that’s been largely unexplored,” DeVito said. “We’re excited to contribute something new that has the potential to change how we approach treatment.”A big focus of the study is the tumor microenvironment, the community of immune cells, cancer cells, and other structures within and around each tumor. Using two advanced technologies, the team examines the tumor at both the protein and RNA levels.Working with John Hickey, PhD, assistant professor of biomedical engineering at the Pratt School of Engineering, the team employed the Codex assay in the study. By using special antibodies to highlight different cell types, the assay lets researchers map where various immune cells are and how close they are to the tumor.The team also partnered with Erika Crosby, PhD, assistant professor in the Duke Department of Surgery, to use the Xenium assay, which analyzes the RNA within cells. This helps confirm the protein‑level findings while revealing additional details that might not show up at the protein stage.Early results show meaningful differences between patients who respond to chemotherapy and those who don’t. Some immune cells appear in higher numbers in people who respond well, suggesting these may serve as early indicators of how effective chemotherapy might be.“Without this collaboration between surgery and biomedical engineering, locating and reviewing patient records and samples would have been far more time‑consuming,” DeVito said. “Everything came together at the right time: the technology, the expertise, and access to the right samples. That’s what makes a project like this possible.”A major boost for this work also came from CRUSH Colorectal Cancer, which supports early‑stage ideas that need initial funding before they can compete for larger grants.“CRUSH provided the seed funding that allowed us to get started,” DeVito said. “An added benefit is that any data generated becomes a shared resource for the entire GI oncology team at Duke.”Looking ahead, the team plans to expand their research into mouse models in collaboration with Jatin Roper, MD, that mimic how colorectal cancer spreads to the liver. This could help them test the biomarkers they discover and explore new treatment strategies in the lab.“Ultimately, everything we’re doing comes back to the patient,” Chang said. “We want to find better ways to treat this cancer, especially for patients who don’t have many options today.”The annual CRUSH Colorectal Cancer 5K will be held on March 14. Learn more about the event.
